The role of clinical pharmacology in optimizing antiretroviral therapy

British Journal of Clinical Pharmacology

Volumn 55, Issue 5, 2003, Pages 473-476

  Back, David J ^a   Khoo, Saye H ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; GLYCOPROTEIN P; INDINAVIR; LAMIVUDINE; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 5; NELFINAVIR; NEVIRAPINE; ORGANIC ANION TRANSPORTER; OROSOMUCOID; PREGNANE X RECEPTOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

CLINICAL PHARMACOLOGY; CONFERENCE PAPER; DRUG COST; DRUG DISPOSITION; DRUG PROTEIN BINDING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; PATIENT COMPLIANCE; PATIENT MONITORING; PHARMACOGENOMICS; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GENOME, HUMAN; HIV INFECTIONS; HUMANS; MONITORING, PHYSIOLOGIC; PHARMACOLOGY, CLINICAL;

EID: 0038730596     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01843.x     Document Type: Conference Paper

References (14)

1. Palella F, Chmiel J, Moorman AC, et al. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002; 16: 1617-1626.
2. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active anti-retroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353: 863-868.
3. Back DJ, Gatti G, Fletcher C, et al. Therapeutic drug monitoring m HIV infection: current status and future directions. AIDS 2002; 16(Suppl 1): S5-S37.
4. van Heeswijk RPG. Critical issues in therapeutic drug monitoring of antiretroviral drugs. Ther Drug Monit 2002; 24: 323-331.
5. Flexner CW, Piscitelli SC. Concentration-targeted therapy and the future of HIV management. AIDS 2002; 16(Suppl 1): S1-S3.
6. Fletcher CV, Cheng H, Fiscus S, et al. The inhibitory quotient (IQ) for saquinavir (SQV) predicts virologic response to salvage therapy. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, WA, 24-28 February, 2002 [Abst. 129].
7. Phillips E, Tseng A, Walker S, et al. The use of virtual inhibitory quotient (vIQ) in antiretroviral (ART) -experienced patients taking amprenavir/lopinavir combinations. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, WA, 24-28 February, 2002 [Abstr. 130].
8. Burger D. Therapeutic drug monitoring: A must for clinical practice? First IAS Conference on HIV Pathogenesis and Treatment. Buenos Aries, Argentina, 8-11 July, 2001 [Abstr. 54].
9. Hoggard PG, Kewn S, Lloyd J, et al. Virological failure is associated with decreased 3TC triphosphate (3TCTP) and ratio of 3TCTP/endogenous deoxycytidine triphosphate in HIV-infected individuals. Ninth Conference on Retroviruses and Opportunistic Infections.. Seattle, WA, 24-28 February, 2002 [Abstr.455].
10. Pirmohamed M, Back DJ. The pharmacogenomics of HIV therapy. The Pharmacogenomics J 2001; 1: 243-253.
11. Yuasa I, Umetsu K, Vogt U, et al. Human orosomucoid polymorphism: molecular basis of the three common ORM1 alleles, ORM1*F1, ORM1*F2, and ORM1*S. Hum Genet 1997; 99: 393-398.
12. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
13. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1 infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30-36.
14. Zhang J, Kuehl P, Green ED, et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001; 11: 551-552.